<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602537</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH060353-02</org_study_id>
    <secondary_id>R01MH060353-02</secondary_id>
    <secondary_id>2R01MH060353-06A2</secondary_id>
    <nct_id>NCT00602537</nct_id>
  </id_info>
  <brief_title>Antidepressant Therapy in Treating Bipolar Type II Major Depression</brief_title>
  <official_title>Treatment of Bipolar Type II Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the safety and effectiveness of antidepressant therapy versus mood
      stabilizing therapy in treating people with bipolar type II major depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bipolar type II (BP II) depression affects 2.5% of the U.S. adult population. People with BP
      II disorder do not experience the manic episodes that are characteristic of BP I disorder,
      but rather they experience more modest mood swings with a greater number of major depressive
      episodes (MDEs). These MDEs are associated with high rates of disease and death. The
      treatment of BP II depression remains a challenge for clinicians. Mood stabilizer (MS)
      monotherapy is the current recommended treatment for BD II MDE, but there is reason to
      believe that antidepressant drug (AD) monotherapy could also be an effective treatment.
      However, concerns over AD-induced manic switch episodes have limited the use of this
      treatment option. Preliminary studies using the ADs fluoxetine or venlafaxine have shown
      success in treating and lowering the manic switch rate of those with BP II MDE. This study
      will compare the safety and effectiveness of AD monotherapy versus MS monotherapy in treating
      people with BP II major depression.

      Participation in this double-blind study will last up to 9 months. After screening, which
      includes a medical and psychiatric history review, a physical exam, an electrocardiogram
      (EKG) test, clinical laboratory tests, a urine-based drug test, and a pregnancy test if
      applicable, participants will be randomly placed into one of two treatment groups.
      Participants in the AD monotherapy group will be treated with venlafaxine, and participants
      in the MS monotherapy group will be treated with lithium. During the first 12 weeks, there
      will be a total of nine study visits lasting between 45 and 60 minutes. In these visits,
      participants will receive their study drug and will undergo various assessments, including a
      review of medication history and side effects, vital sign measurements, and questionnaires
      about depression and daily functioning. Blood samples will be taken at most visits.

      Participants who respond well during the initial 12 weeks of therapy with either drug will
      have the option to continue treatment for 6 additional months. During this time, participants
      will continue their assigned treatment and will attend five monthly study visits that will
      repeat previous assessments and procedures.

      For information on a related study, please follow this link:

      http://clinicaltrials.gov/show/NCT00044616
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depressive Relapse</measure>
    <time_frame>Weeks 16, 20, 24, 30, 36</time_frame>
    <description>These subjects must be responders. Outcome measures were obtained at continuation weeks. Participant would be considered &quot;depressive relapse&quot; if relapsed by any of these times.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-Emergent Mood Symptoms</measure>
    <time_frame>Measured at Weeks 12 and 36</time_frame>
    <description>These subjects must be responders.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antidepressant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mood stabilizer therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>75 to 375 mg</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Carbonate</intervention_name>
    <description>300 to 2400 mg</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for Axis I bipolar II disorder

          -  Meets DSM-IV criteria for Axis I major depressive episode

          -  Score of 16 on 17-item HAM-D rating scale

          -  Not taking monoamine oxidase inhibitors (MAOI) for more than 2 weeks prior to study
             entry

          -  Willing to use an effective form of birth control throughout the study

        Exclusion Criteria:

          -  History of mania

          -  Current primary Axis I diagnosis other than bipolar II disorder

          -  Alcohol or drug dependence within 3 months prior to study entry

          -  Contraindication to treatment with venlafaxine or lithium

          -  Unstable medical condition (e.g., thyroid disease, hypertension, or angina pectoris)

          -  Pregnant or breastfeeding

          -  Experiencing suicidal thoughts

          -  Requires hospitalization

          -  Requires concurrent neuroleptic or MS therapy

          -  Requires concurrent AD therapy

          -  Current psychotic features

          -  Inadequate trial of therapy at the time of initial screening visit

          -  History of intolerance to either venlafaxine or lithium

          -  Unlikely to participate in a 36-week trial

          -  Presence of apparent secondary gain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J. DeRubeis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Research Unit - University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-3309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <results_first_submitted>November 10, 2016</results_first_submitted>
  <results_first_submitted_qc>April 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar Type II Disorder</keyword>
  <keyword>Hypomania</keyword>
  <keyword>Antidepressant</keyword>
  <keyword>Mood Stabilizer</keyword>
  <keyword>Venlafaxine</keyword>
  <keyword>Lithium Carbonate</keyword>
  <keyword>Major Depressive Episode</keyword>
  <keyword>Hypomanic Episodes</keyword>
  <keyword>Prevention of Depression Relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Antidepressant Therapy</title>
          <description>Venlafaxine: 75 to 375 mg</description>
        </group>
        <group group_id="P2">
          <title>Mood Stabilizer Therapy</title>
          <description>Lithium Carbonate: 300 to 2400 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>12 Week Double Blind Comparison</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Responded</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow Up Study Comparison</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antidepressant Therapy</title>
          <description>Venlafaxine: 75 to 375 mg</description>
        </group>
        <group group_id="B2">
          <title>Mood Stabilizer Therapy</title>
          <description>Lithium Carbonate: 300 to 2400 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="11.4"/>
                    <measurement group_id="B2" value="43.1" spread="15.2"/>
                    <measurement group_id="B3" value="42.2" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Inter-episode recovery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age 1st major depressive episode</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.0" spread="7.7"/>
                    <measurement group_id="B2" value="17.4" spread="5.4"/>
                    <measurement group_id="B3" value="18.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age 1st hypomanic episode</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.7" spread="7.6"/>
                    <measurement group_id="B2" value="16.2" spread="10.0"/>
                    <measurement group_id="B3" value="19.4" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of lifetime major depressive episodes</title>
          <units>Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.4" spread="50.4"/>
                    <measurement group_id="B2" value="33.3" spread="49.7"/>
                    <measurement group_id="B3" value="29.9" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of lifetime hypomanic episodes</title>
          <units>Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.8" spread="66.4"/>
                    <measurement group_id="B2" value="32.2" spread="47.3"/>
                    <measurement group_id="B3" value="41.9" spread="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HRSD score</title>
          <description>This scale refers to the 17-item Hamilton Rating Scale for Depression and measures patient depressive severity. The scale ranges from 0 to 52, with higher scores representing worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.4" spread="3.6"/>
                    <measurement group_id="B2" value="18.8" spread="3.3"/>
                    <measurement group_id="B3" value="19.2" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline YMRS score</title>
          <description>This scale refers to the Young Mania Rating Scale and measures manic symptoms. The scale ranges from a minimum score of 0 to a maximum score of 60, with higher scores representing worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" spread="1.7"/>
                    <measurement group_id="B2" value="0.6" spread="1.4"/>
                    <measurement group_id="B3" value="0.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration major depressive episode</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" lower_limit=".75" upper_limit="60"/>
                    <measurement group_id="B2" value="4.0" lower_limit="0" upper_limit="396"/>
                    <measurement group_id="B3" value="4" lower_limit="0" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HRSD Score for Follow-Up study</title>
          <description>This scale refers to the 17-item Hamilton Rating Scale for Depression and measures patient depressive severity. The scale ranges from 0 to 52, with higher scores representing worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="2.8"/>
                    <measurement group_id="B2" value="4.4" spread="3.4"/>
                    <measurement group_id="B3" value="4.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Depressive Relapse</title>
        <description>These subjects must be responders. Outcome measures were obtained at continuation weeks. Participant would be considered &quot;depressive relapse&quot; if relapsed by any of these times.</description>
        <time_frame>Weeks 16, 20, 24, 30, 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antidepressant Therapy</title>
            <description>Venlafaxine: 75 to 375 mg</description>
          </group>
          <group group_id="O2">
            <title>Mood Stabilizer Therapy</title>
            <description>Lithium Carbonate: 300 to 2400 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Depressive Relapse</title>
          <description>These subjects must be responders. Outcome measures were obtained at continuation weeks. Participant would be considered &quot;depressive relapse&quot; if relapsed by any of these times.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-Emergent Mood Symptoms</title>
        <description>These subjects must be responders.</description>
        <time_frame>Measured at Weeks 12 and 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antidepressant Therapy</title>
            <description>Venlafaxine: 75 to 375 mg</description>
          </group>
          <group group_id="O2">
            <title>Mood Stabilizer Therapy</title>
            <description>Lithium Carbonate: 300 to 2400 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Emergent Mood Symptoms</title>
          <description>These subjects must be responders.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any subsyndromal hypomania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Antidepressant Therapy</title>
          <description>Venlafaxine: 75 to 375 mg</description>
        </group>
        <group group_id="E2">
          <title>Mood Stabilizer Therapy</title>
          <description>Lithium Carbonate: 300 to 2400 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jay Amsterdam</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>(215) 662-3462</phone>
      <email>jamsterd@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

